A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 7 sites in Korea, Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-04-21.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 23rd largest by enrollment, is one of 5 that started in 2005, is one of 29 in phase 4, and was the 28th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 14th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2005, is one of 16 in phase 4, and was the 21st registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of PEGASYS (peginterferon alfa-2a) in patients with HBeAg positive chronic hepatitis B. Patients will be stratified into group A (treatment naïve patients) or B (YMDD mutant patients). All patients will receive PEGASYS 180 micrograms subcutaneously once weekly for 48 weeks, followed by 24 weeks of treatment-free follow up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
Drug: peginterferon alfa-2a [Pegasys]
Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.
Drug: peginterferon alfa-2a [Pegasys]
Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72
Participants who had Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) levels below 100,000 copies per milliliter (mL) at the end of follow-up (EOF) period (24 weeks after the end of treatment) were classified as responders.
Time frame: Week 72
Percentage of Participants With Hepatitis B Virus e Antigen Loss At Week 72
Participants with loss of hepatitis B virus e antigen (HBeAg) at the EOF period (24 weeks after the end of treatment) were classified as responders.
Time frame: Week 72
Percentage of Participants With ALT Normalization At Week 48 and Week 72
Participants with ALT less than the upper limit of normal (ULN) at end of treatment (EOT) and EOF period were responders.
Time frame: Week 48 and Week 72
Percentage of Participants With Hepatitis B Virus DNA Below the Limit of Detection At Week 48 and Week 72
Participants with HBV-DNA below the limit of detection i.e. \<174 copies/mL at EOT and EOF period were responders.
Time frame: Week 48 and Week 72
Percentage of Participants With a Combined Response At Week 48 and Week 72
A responder with Combined Response was a participant with HBV-DNA\<100,000 copies/mL, HBeAg seroconversion (i.e. loss of HBeAg and presence of anti-HBe) and ALT normalization at EOT and EOF period.
Time frame: Week 48 and Week 72
Percentage of Participants With Hepatitis B Virus e Antigen Seroconversion
A responder was a participant with loss of HBeAg and presence of anti-HBe at EOT and EOF period.
Time frame: Week 48 and Week 72
Percentage of Participants With Loss of Hepatitis B Surface Antigen At Week 48 and Week 72
A responder was a participant who were analysed with loss of Hepatitis B Surface Antigen (HBsAg) at EOT and EOF period.
Time frame: Week 48 and Week 72
Percentage of Participants With Hepatitis B Surface Antigen Seroconversion At Week 48 and Week 72
A responder was a participant with loss of HBsAg and presence of anti-HBs at EOT and EOF period.
Time frame: Week 48 and Week 72
Number of Participants With Any Adverse Events and Any Serious Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious Adverse Events (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Participants with any AEs and any SAEs have been presented.
Time frame: Up to Week 72
A total of 150 participants were enrolled in this study conducted from 26 October 2005 to 24 June 2008 at 7 centers in Republic of Korea.
| Milestone | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Started | 86 | 64 |
| Completed | 65 | 49 |
| Not completed | 21 | 15 |
| Withdrew: Adverse event | 10 | 9 |
| Withdrew: Lack of efficacy | 4 | 3 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Treatment refusal | 2 | 1 |
| Withdrew: High alanine aminotransferase (alt) | 0 | 1 |
Participants who had Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) levels below 100,000 copies per milliliter (mL) at the end of follow-up (EOF) period (24 weeks after the end of treatment) were classified as responders.
| percentage of participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72 | 20.9 (12.9 to 31.0) | 21.9 (12.5 to 34.0) |
Participants with loss of hepatitis B virus e antigen (HBeAg) at the EOF period (24 weeks after the end of treatment) were classified as responders.
| Percentage of participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Percentage of Participants With Hepatitis B Virus e Antigen Loss At Week 72 | 20.9 (12.9 to 31.0) | 23.4 (13.8 to 35.7) |
Participants with ALT less than the upper limit of normal (ULN) at end of treatment (EOT) and EOF period were responders.
| percentage of participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Week 48 (EOT) | 34.9 (24.9 to 45.9) | 29.7 (18.9 to 42.4) |
| Week 72 (EOF) | 36.0 (26.0 to 47.1) | 29.7 (18.9 to 42.4) |
Participants with HBV-DNA below the limit of detection i.e. \<174 copies/mL at EOT and EOF period were responders.
| Percentage of participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Week 48 (EOT) | 10.5 (4.9 to 18.9) | 10.9 (4.5 to 21.2) |
| Week 72 (EOF) | 3.5 (0.7 to 9.9) | 9.4 (3.5 to 19.3) |
A responder with Combined Response was a participant with HBV-DNA\<100,000 copies/mL, HBeAg seroconversion (i.e. loss of HBeAg and presence of anti-HBe) and ALT normalization at EOT and EOF period.
| Percentage of participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Week 48 (EOT) | 8.1 (3.3 to 16.1) | 9.4 (3.5 to 19.3) |
| Week 72 (EOF) | 9.3 (4.1 to 17.5) | 14.1 (6.6 to 25.0) |
A responder was a participant with loss of HBeAg and presence of anti-HBe at EOT and EOF period.
| Percentage of participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Week 48 (EOT) | 15.1 (8.3 to 24.5) | 23.4 (13.8 to 35.7) |
| Week 72 (EOF) | 20.9 (12.9 to 31.0) | 21.9 (12.5 to 34.0) |
A responder was a participant who were analysed with loss of Hepatitis B Surface Antigen (HBsAg) at EOT and EOF period.
| Percentage of participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Week 48 (EOT) | 1.2 (0.03 to 6.3) | 1.6 (0.04 to 8.4) |
| Week 72 (EOF) | 1.2 (0.03 to 6.3) | 1.6 (0.04 to 8.4) |
A responder was a participant with loss of HBsAg and presence of anti-HBs at EOT and EOF period.
| Percentage of participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Week 48 (EOT) | 1.2 (0.03 to 6.3) | 0.0 (0.0 to 0.0) |
| Week 72 (EOF) | 1.2 (0.03 to 6.3) | 1.6 (0.04 to 8.4) |
An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious Adverse Events (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Participants with any AEs and any SAEs have been presented.
| Participants | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Any AEs | 75 | 54 |
| Any SAEs | 4 | 5 |
Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN Alfa-2a (Treatment naïve) | — | 4/86 (4.7%) | 69/86 (80.2%) |
| PEG-IFN Alfa-2a (YMDD Mutant) | — | 5/64 (7.8%) | 52/64 (81.3%) |
| Event | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| Liver function test abnormalInvestigations | 0/86 | 2/64 |
| Abdominal pain upperGastrointestinal disorders | 0/86 | 1/64 |
| AppendicitisGastrointestinal disorders | 0/86 | 1/64 |
| PyrexiaGeneral disorders | 1/86 | 1/64 |
| Cholecystitis acuteHepatobiliary disorders | 0/86 | 1/64 |
| Wrist fractureInjury, poisoning and procedural complications | 0/86 | 1/64 |
| LymphadenopathyBlood and lymphatic system disorders | 1/86 | 0/64 |
| ExomphalosGastrointestinal disorders | 1/86 | 0/64 |
| HaemorrhoidsGastrointestinal disorders | 1/86 | 0/64 |
| BronchopneumoniaRespiratory, thoracic and mediastinal disorders | 1/86 | 0/64 |
| Event | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 34/86 | 24/64 |
| NeutropeniaBlood and lymphatic system disorders | 21/86 | 18/64 |
| FatigueGeneral disorders | 16/86 | 17/64 |
| HeadacheNervous system disorders | 16/86 | 15/64 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 10/86 | 13/64 |
| Influenza like illnessGeneral disorders | 11/86 | 12/64 |
| PruritusSkin and subcutaneous tissue disorders | 11/86 | 12/64 |
| PainGeneral disorders | 13/86 | 6/64 |
| DyspepsiaGastrointestinal disorders | 10/86 | 1/64 |
| Liver function test abnormalInvestigations | 10/86 | 7/64 |
Baseline characteristics were analysed on Intent-to-treat (ITT) population which included all participants who received at least one dose of study drug. The ITT and the safety populations were identical.
| Age, Continuous(Years) | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) | Total |
|---|---|---|---|
| Mean | 35.3 ± 9.20 | 36.8 ± 9.0 | 35.9 ± 9.1 |
| Sex: Female, Male(Participants) | PEG-IFN Alfa-2a (Treatment naïve) | PEG-IFN Alfa-2a (YMDD Mutant) | Total |
|---|---|---|---|
| Female | 23 | 10 | 33 |
| Male | 63 | 54 | 117 |
The record gives a start of Oct 2005, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 7 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a